Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.30 USD
Change Today +0.02 / 1.56%
Volume 131.2K
UPI On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

uroplasty inc (UPI) Snapshot

Open
$1.25
Previous Close
$1.28
Day High
$1.33
Day Low
$1.25
52 Week High
04/4/14 - $4.05
52 Week Low
01/26/15 - $1.05
Market Cap
28.8M
Average Volume 10 Days
75.4K
EPS TTM
$-0.28
Shares Outstanding
22.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for UROPLASTY INC (UPI)

Related News

No related news articles were found.

uroplasty inc (UPI) Related Businessweek News

No Related Businessweek News Found

uroplasty inc (UPI) Details

Uroplasty, Inc., a medical device company, develops, manufactures, and markets products for the treatment of voiding dysfunctions primarily in the United States. It principally offers Urgent PC Neuromodulation system, a minimally-invasive, neuromodulation system that delivers percutaneous tibial nerve stimulation for office-based treatment of overactive bladder and the associated symptoms of urinary urgency, urinary frequency, and urge incontinence. The company also provides Macroplastique implants, an injectable and urethral bulking agent for the treatment of adult female stress urinary incontinence due to intrinsic sphincter deficiency, as well as for the treatment of male stress incontinence, fecal incontinence, vocal cord rehabilitation, and vesicoureteral reflux. In addition, it offers Macroplastique products for treatment of vesicoureteral reflux; Urgent PC System for the treatment of fecal incontinence; PTQ Implants, which provides a minimally-invasive, soft-textured permanent implant for treatment of fecal incontinence; and VOX Implants, a silicone elastomer bulking material for vocal cord rehabilitation applications, as well as distributes wound care products. The company sells its products primarily to urologists, urogynecologists, and gynecologists through a direct sales organization in the United Kingdom, the Netherlands, Switzerland, and the Nordic countries, as well as through distributors in other markets. Uroplasty, Inc. was incorporated in 1992 and is headquartered in Minnetonka, Minnesota.

113 Employees
Last Reported Date: 01/27/15
Founded in 1992

uroplasty inc (UPI) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $589.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $212.7K
Vice President of Corporate Development
Total Annual Compensation: $195.1K
Senior Vice President of Global Sales and Mar...
Total Annual Compensation: $332.3K
Compensation as of Fiscal Year 2014.

uroplasty inc (UPI) Key Developments

Uroplasty, Inc., Vision-Sciences Inc. - M&A Call

To discuss the proposed merger between Uroplasty, Inc. and Vision-Sciences

Uroplasty, Inc. Presents at 27th Annual ROTH Conference, Mar-10-2015 04:00 PM

Uroplasty, Inc. Presents at 27th Annual ROTH Conference, Mar-10-2015 04:00 PM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States. Speakers: Brett A. Reynolds, Chief Financial Officer, Principal Accounting Officer, Senior Vice President and Secretary, Robert C.E. Kill, Chairman, Chief Executive Officer and President.

Vision-Sciences's Merger With Uroplasty Will Lead To Future Acquisitions

Howard Zauberman, President and Chief Executive Officer of Vision-Sciences Inc. (NasdaqCM:VSCI) said during the earnings call for the third quarter of 2015 that the combined company, Cogentix Medical, as a result of Vision-Sciences's merger with Uroplasty, Inc. (NasdaqCM:UPI) will have greater resources to invest in future acquisitions, access capital markets and evaluate other growth opportunities. The combined company will be a strong platform from which to grow both organically and through additional strategic acquisitions.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UPI:US $1.30 USD +0.02

UPI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bacterin International Holdings Inc $4.14 USD +0.09
Cardica Inc $0.59 USD -0.01
Stereotaxis Inc $2.08 USD +0.01
Urologix Inc $0.09 USD 0.00
Vision Sciences Inc/DE $0.44 USD +0.02
View Industry Companies
 

Industry Analysis

UPI

Industry Average

Valuation UPI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.1x
Price/Book 3.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UROPLASTY INC, please visit www.uroplasty.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.